Webcast: Advances in Screening, Diagnosis, and Treatment of Iron Deficiency in Heart Failure Patients

Iron deficiency (ID) with or without anemia is a common and important comorbidity in patients with heart failure (HF), and it can have significant impacts on morbidity and mortality.  Despite this burden, the diagnosis and assessment of ID is not widely sought by clinicians that see patients with HF, leading to underdiagnosis, misdiagnosis, and delayed treatment.  Recent trials and evidence have shown that i.v. iron repletion in HF patients with ID can improve symptoms, quality of life, and outcomes, and this evidence has been reflected accordingly in the updated HF guidelines. During this webinar, experts will discuss the latest advances in the screening, diagnosis, and treatment of ID in patients with HF.

This activity is part of the Iron Deficiency in Heart Failure Digital Education Hub.

Target Audience

The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Discuss the prevalence and clinical burden of iron deficiency in HF patients.
  • Summarize current and emerging diagnostic approaches aimed to optimize the early diagnosis of ID in patients with HF.
  • Review the efficacy and safety of intravenous iron repletion for the treatment of iron deficiency in patients with HF.
  • Summarize guideline recommendations for the treatment of iron deficiency in patients with HF.
Course summary
Available credit: 
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
08/31/2022
Course expires: 
08/31/2023
Rating: 
5

Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
The Mary and Gordon Cain Chair in Cardiology and Professor of Medicine
Associate Provost of Faculty Affairs,
Senior Associate Dean of Faculty Development
Director, Winters Center for Heart Failure Research
Assoc. Director, Cardiovascular Research Institute
Baylor College of Medicine
Immediate Past President of the HFSA
Houston, TX

Dr. Bozkurt discloses discloses the following:

Consulting Fees: Amgen, Bristol Myers Squibb, scPharmaceuticals, Baxter Healthcare Corporation, Sanofi-Aventis, Relypsa, Vifor.

Financial Relationship: Serve on the Clinical Event Committee for GUIDE HF Trial sponsored by Abbott Vascular ata Safety Monitoring Committee of ANTHEM trial (Autonomic REGULATION Therapy to Enhance Myocardial Function and Reduce progression of Heart Failure with reduced ejection fraction) sponsored by Liva Nova Data Safety Monitoring of A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Effectiveness of CRD-740 (PDE9 inhibitor) in Subjects with Chronic Heart Failure Cardurion

 

Javed Butler, MD, MPH, MBA
President, Baylor Scott and White Research Institute, Dallas, TX
Distinguished Professor of Medicine , University of Mississippi, Jackson, MS

Dr. Butler discloses the following: 

Consulting Fees: Abbott, Adrenomed, Amgen, Applied Therapeutics, Array, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharma, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordisk, Relypsa, Roche, Sequana Medical, and Vifor

Speakers' Bureau: Novartis, Boehringer Ingelheim-Lilly, Astra Zeneca, Janssen

 

Gurusher S. Panjrath, MD, FACC, FAHA
Director, Heart Failure and Mechanical Circulatory Support Program
Associate Professor of Medicine
George Washington University School of Medicine
Washington, DC

Dr. Panjrath has nothing to disclose.

 

Ileana L. Piña, MD, MPH, FAHA, FACC, FHFSA
Clinical Professor of Medicine
Central Michigan University 
Adjunct Professor of Epi/Biostats, Case Western Reserve University
Senior Staff Fellow for FDA, CDRH, Medical Officer

Dr. Piña has nothing to disclose.

 

ESTIMATED TIME TO COMPLETE ACTIVITY
1.0 hour

EDUCATIONAL GRANT SUPPORT
This activity is supported by an educational grant from American Regent.

JOINT PROVIDERSHIP STATEMENT

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians

PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST ACCREDITATION STATEMENT
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Credit Designation
Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number (UAN): 0530-9999-22-105-H01-P

This is a knowledge-based activity. 

GLOBAL CONTACT INFORMATION
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com..

DISCLOSURES

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager Reported Financial Relationship
Rhys Williams, MSN, FNP-C, RNNothing to disclose.
Lindsay BorvanskyNothing to disclose.
Andrea FunkNothing to disclose.
Liddy KnightNothing to disclose.
Ashley CannNothing to disclose.
Karin McAdamsNothing to disclose.
Shpetim Karandrea, PhDNothing to disclose.
Neha Agarwal, PhDNothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT

This activity is complimentary and available during the period August 31, 2022 through August 31, 2023. Learners must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 70% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be be available for print.

For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org. For questions about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Available Credit

  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.